Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $32000.0.

  • Assembly Biosciences' Depreciation & Amortization (CF) fell 303.03% to $32000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $129000.0, marking a year-over-year decrease of 2872.93%. This contributed to the annual value of $129000.0 for FY2024, which is 7133.33% down from last year.
  • Latest data reveals that Assembly Biosciences reported Depreciation & Amortization (CF) of $32000.0 as of Q3 2025, which was down 303.03% from $32000.0 recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Depreciation & Amortization (CF) registered a high of $134000.0 during Q3 2022, and its lowest value of $32000.0 during Q1 2024.
  • Over the past 5 years, Assembly Biosciences' median Depreciation & Amortization (CF) value was $116000.0 (recorded in 2023), while the average stood at $86315.8.
  • As far as peak fluctuations go, Assembly Biosciences' Depreciation & Amortization (CF) surged by 1260.5% in 2022, and later crashed by 7460.32% in 2024.
  • Assembly Biosciences' Depreciation & Amortization (CF) (Quarter) stood at $120000.0 in 2021, then rose by 3.33% to $124000.0 in 2022, then tumbled by 32.26% to $84000.0 in 2023, then crashed by 61.9% to $32000.0 in 2024, then changed by 0.0% to $32000.0 in 2025.
  • Its last three reported values are $32000.0 in Q3 2025, $32000.0 for Q2 2025, and $33000.0 during Q1 2025.